CClinicalTrials.gg
Status unknownNCT04924517Updated Mar 31, 2022

Extended Evening Fasting: Metabolic Health and Energy Balance

An interventional study of Extended Evening Fasting and Control in Obesity, sponsored by Nottingham Trent University. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Nottingham Trent University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study will compare metabolic and feeding behaviour responses to 4 days of extended evening fasting vs. a control trial

Read the detailed description

Humans have evolved as a diurnal species, internally governed by the circadian system, which dictates our hormone regulation. 'Chrononutrition' is a sub-discipline which combines food timing with circadian physiology. The most popular method of time-restricted feeding in the UK is to skip breakfast. However, data from several meta-analysis have shown that skipping breakfast is associated with weight gain and insulin resistance, likely due to eating later into the evening/night and therefore, out of sync with our circadian rhythm. Recent research has shown that skipping dinner (evening fasting) has improved markers of cardio-metabolic health in clinical populations, although these are typically from longer-term studies. Despite these promising findings, it is not yet known whether these findings are population specific.

Therefore, the investigators are interested in examining the metabolic response pre and post intervention to see whether these promising findings can translate into a healthy population. Furthermore, the investigators will be monitoring subjective appetite, energy intake and expenditure to assess whether there is any short-term adaptation to a specific feeding window.

02

Conditions studied

  • Obesity

Keywords

  • Chrononutrition
  • Energy balance
  • Intermittent fasting
  • Appetite hormones
03

In context

Lead sponsor

Nottingham Trent University is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Non-smokers.

    • Have maintained a stable weight for 6 months (self-reported).
    • No history of gastric, digestive, cardiovascular or renal disease (self reported).
    • Female specific: must be using a monophasic, low dose combined OCP (containing less than 50μg oestradiol and a synthetic progestin) OR females with regular menstrual cycles (self-reported).

Exclusion criteria

Exclusion Criteria:

  • Severe food allergies, dislike or intolerance of study foods or drinks.

    • Currently undergoing a lifestyle intervention (structured diet or exercise)
    • Diagnosis of a condition or currently undergoing treatment therapy known to affect glucose or lipid metabolism (e.g., type-2 diabetes, taking statins), or contraindications to exercise.
    • Use of medication or supplements that may affect hormone concentrations.
    • Excessive alcohol consumption (>14 units/week).
    • Intensive training schedule (>10 hours/week).
    • Female specific: currently pregnant or breastfeeding, the use of any hormonal contraception, and the self-reporting of short (\<24 d), long (>35 d), or irregular menstrual cycles.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Extended Evening Fasting

    Participants will eat between 8am-4pm

    Behavioral: Extended Evening Fasting

  • Active comparator
    Control

    Participants will eat between 8am-8pm

    Behavioral: Control

Interventions

  • BehavioralExtended Evening Fasting

    Participants will undertake 4 days of extended evening fasting (feeding between 8am-4pm). The participants will visit the laboratory on day 1, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.

  • BehavioralControl

    Participants will undertake 4 days of a standard western feeding pattern (feeding between 8am-8pm). The participants will visit the laboratory on day 1, following a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.

06

What researchers measure

Primary outcomes

  1. Glycaemic control (Baseline)

    A metabolic assessment lasting 3.5 hours will take place following a standardised, laboratory-based meal. The investigators will be taking periodic capillary and venous blood samples to measure post-prandial glucose and insulin, which together comprise 'glycaemic control'.

    Time frame: 3.5 hours following the standardised breakfast meal on day 1.

  2. Glycaemic control (Post intervention)

    A metabolic assessment lasting 3.5 hours will take place following a standardised, laboratory-based meal. The investigators will be taking periodic capillary and venous blood samples to measure post-prandial glucose and insulin, which together comprise 'glycaemic control'.

    Time frame: 3.5 hours following the standardised breakfast meal on day 4.

  3. Energy Intake (Kilocalories)

    Energy intake will be measured both during lab and outside of the laboratory when the participants are free-living. During lab, energy intake will be measured through ad-libitum feeding buffet where 20 minutes will be permitted to eat as much or as little as they desire, until 'comfortably full and satisfied', followed by post-feeding measurement of the remaining food. Outside of laboratory feeding will also be monitored through food diary's and weighing any investigator issued meals.

    Time frame: Day 1 to day 4.

  4. Energy expenditure

    Energy expenditure will be measured via a chest-worn device (Actiheart) which combines heart rate and accelerometry to gauge calories expended.

    Time frame: Day 1 to day 4.

Secondary outcomes

  1. Cortisol awakening response

    The cortisol awakening response will be measured on the final morning of each trial.

    Time frame: Five samples will be collected by the participant within the first hour of waking on day 5.

  2. Visual Analogue Scale for Subjective Ratings of Appetite

    Subjective appetite will be measured on mobile devices via a software which replicates a 100mm visual analogue scale. The scale is divided into subscales of different appetite perceptions including: hunger, fullness, desire to eat and prospective food consumption. (i.e. from 0 - 100), with a rating of 100 fully supporting the perception and a rating of 0 fully opposing the perception.

    Time frame: Every 2 hours between 8am-10pm from day 1 to day 4.

  3. Acylated Ghrelin (appetite hormone)

    Acylated Ghrelin will be measured from the venous samples taken during the post-prandial period following the standardised meal.

    Time frame: 3.5 hours following the standardised breakfast meal on day 1 and day 4.

  4. PYY (appetite hormone)

    PYY will be measured from the venous samples taken during the post-prandial period following the standardised meal.

    Time frame: 3.5 hours following the standardised breakfast meal on day 1 and day 4.

  5. Carbohydrate oxidation

    Investigators will be collecting expired air into Douglas bags, and measuring the VO2 and VCO2 concentration to calculate carbohydrate oxidation.

    Time frame: During laboratory visits on day 1 and day 4 [baseline, 60min, 120min, 180min]

  6. Fat oxidation

    Investigators will be collecting expired air into Douglas bags, and measuring the VO2 and VCO2 concentration to calculate fat oxidation.

    Time frame: During laboratory visits on day 1 and day 4 [baseline, 60min, 120min, 180min]

07

Study locations

1 of 1 sites recruiting
  • Nottingham Trent University
    Nottingham, Greater London NG11 8NS, United Kingdom
    • David Clayton, PhD · Contact · david.clayton@ntu.ac.uk · (+44) 115 848 5514
    • William Mode, MRes · Principal investigator
    • David Clayton, PhD · Sub investigator
    • John Hough, PhD · Sub investigator
    • Ruth James, PhD · Sub investigator
    • Ian Varley, PhD · Sub investigator
    Recruiting
08

References and documents

Publications

  • Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metab. 2018 Jun 5;27(6):1212-1221.e3. doi: 10.1016/j.cmet.2018.04.010. Epub 2018 May 10. PubMed 29754952 ↗
  • Jamshed H, Beyl RA, Della Manna DL, Yang ES, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves 24-Hour Glucose Levels and Affects Markers of the Circadian Clock, Aging, and Autophagy in Humans. Nutrients. 2019 May 30;11(6):1234. doi: 10.3390/nu11061234. PubMed 31151228 ↗
  • Ravussin E, Beyl RA, Poggiogalle E, Hsia DS, Peterson CM. Early Time-Restricted Feeding Reduces Appetite and Increases Fat Oxidation But Does Not Affect Energy Expenditure in Humans. Obesity (Silver Spring). 2019 Aug;27(8):1244-1254. doi: 10.1002/oby.22518. PubMed 31339000 ↗
  • Hutchison AT, Regmi P, Manoogian ENC, Fleischer JG, Wittert GA, Panda S, Heilbronn LK. Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial. Obesity (Silver Spring). 2019 May;27(5):724-732. doi: 10.1002/oby.22449. Epub 2019 Apr 19. PubMed 31002478 ↗
  • Templeman I, Gonzalez JT, Thompson D, Betts JA. The role of intermittent fasting and meal timing in weight management and metabolic health. Proc Nutr Soc. 2020 Feb;79(1):76-87. doi: 10.1017/S0029665119000636. Epub 2019 Apr 26. PubMed 31023390 ↗
  • Popkin BM. The nutrition transition and obesity in the developing world. J Nutr. 2001 Mar;131(3):871S-873S. doi: 10.1093/jn/131.3.871S. PubMed 11238777 ↗
  • Allison KC, Goel N. Timing of eating in adults across the weight spectrum: Metabolic factors and potential circadian mechanisms. Physiol Behav. 2018 Aug 1;192:158-166. doi: 10.1016/j.physbeh.2018.02.047. Epub 2018 Feb 24. PubMed 29486170 ↗
  • St-Onge MP, Ard J, Baskin ML, Chiuve SE, Johnson HM, Kris-Etherton P, Varady K; American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Meal Timing and Frequency: Implications for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. Circulation. 2017 Feb 28;135(9):e96-e121. doi: 10.1161/CIR.0000000000000476. Epub 2017 Jan 30. PubMed 28137935 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04924517
Lead sponsor
Nottingham Trent University
Responsible party
William Mode (Principle Investigator, Nottingham Trent University) — Principal investigator
First posted
Jun 14, 2021
Start date
Sep 14, 2021
Primary completion
Jun 14, 2022 (estimated)
Completion
Jun 14, 2022 (estimated)
Last update
Mar 31, 2022

Study contacts

William Mode, MRes
Contact
william_mode@hotmail.co.uk
+447484751219
David Clayton, PhD
Contact
David.Clayton@ntu.ac.uk
(+44) 115 848 5514

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion